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Abstract
Background: The anti-TNFa therapy has been since its approval by the FDA, along with nonsteroidal
antiinflammatory drugs (NSAIDs), one of the most important therapies for control of spondyloarthritis (SpA). The
onset of Lupus Like Syndrome (LLS) has been described in patients with rheumatoid arthritis (RA) treated with anti-
TNFa therapy but there is little literature on the occurrence of this entity in patients with SpA.
Methods: We studied 57 patients with SpA who received more than 1 year of anti-TNFa therapy (infliximab,
adalimumab or etanercept). Patients were analyzed for the development of LLS, in addition to measuring ANA
levels ≥ 1:160 and Anti-dsDNA (measured by IIF).
Results: In total, 7.01% of patients treated with anti-TNFa had titers of ANA ≥ 1:160, whereas 3.5% of patients had
serum levels of dsDNA. However, only one patient (1.75%; n = 1) experienced clinical symptoms of LLS; this was a
female patient with a history of psoriatic arthritis.
Conclusions: The presence of LLS secondary to anti-TNFa therapy in patients with SpA is observed less frequently
compared with patients with RA. LLS was only detected in a patient with a history of psoriasis since youth, who
developed psoriatic arthritis after 27 years of age and had received anti-TNFa therapy for > 2 years. This may be
because LLS is an entity clearly associated with innate immunity, with little central role of B and T cells.
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Introduction
Lupus Like Syndrome (LLS) is an autoimmune disease
characterized by the appearance of at least one serologi-
cal marker and one non serological marker of systemic
lupus erythematosus (SLE) (according to ACR criteria)
in patients who previously had not; the syndrome com-
monly is associated with use of drugs such as procaina-
mide and hydralazine, [1-3] although other causes exist,
for example, in the context of a paraneoplastic syn-
drome (malignant neoplasms) [4-6]. After approval by
the FDA of anti-TNFa therapy in RA and rheumatic
diseases to such as spondyloarthritis, the emergence of
this syndrome has been described under the name of
lupus-like syndrome [7-10] and other ones under the
name DILE (drug-induced lupus erythematosus), but
classification criteria are not yet well defined and, worse
still, there are few published data on its occurrence in
spondyloarthritis [8,9].
The mechanism by which the therapy against tumor
necrosis factor anti-TNFa induces LLS is not yet well
understood [10]. One hypothesis states that the binding
of anti-TNF drugs to the cell surface containing TNF
induces apoptosis of cells, causing the release of nucleo-
somal autoantigens and induction of anti-dsDNA
[11-16]. A second hypothesis is that suppression of T-
h1 cells by anti-TNF therapy will generate an exuberant
T-h2 response, leading to overproduction of auto-anti-
bodies [5,17]. A third hypothesis suggests that using an
immunosuppressant as anti-TNF associated with dis-
ease-modifying drugs (DMARD), patients are more
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cell activation and therefore the production of auto-anti-
bodies [18-21].
The anti-TNFa therapy is one of the most important
therapies, along with nonsteroidal antiinflammatory
drugs (NSAIDs), for control of spondyloarthritis (SpA),
but still is not classified as disease-modifying drugs
(since it does not alter the disease), but it is classified as
DC-ART (disease controlling antirheumatic therapy).
The onset of LLS in patients with rheumatoid arthritis
(RA) using anti-TNF therapy has been described, but
there is little literature on the occurrence of this entity
in patients with SpA [22-25].
Patients and methods
This is a multicenter, retrospective study that enrolled
57 patients from our rheumatology specialized clinic.
The ethics committee of hospital Universitario de Car-
aras approved the study in accordance with the Declara-
tion of Helsinki.
Where all medical histories of patients with spondy-
loarthritis were reviewed according to the ASAS classifi-
cation and the modified New York criteria; our patients
had received more than 1 year of anti-TNFa biologic
therapy: infliximab, adalimumab and etanercept. We
recorded the duration of the disease, the activity
measured using the Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI), time receiving anti-TNF ther-
apy, and use of other immunosuppressive therapies.
LLS was defined in patients who showed all the follow-
ing conditions: 1. A temporal relationship between clinical
signs/symptoms and anti-TNFa treatment; 2. At least, one
serological test positive for SLE (according to ACR), anti-
nuclear antibodies (ANA), anti-dsDNA, or anti-cardiolipin
(ACA); and 3. At least one ACR criteria: arthritis, serositis,
hematological disorder, malar erythema.
Moderate SLL was defined in patients who had arthral-
gia and/or mialgia that subsided with the use of analgesic
or nonsteroidal antiinflammatory drugs (NSAIDs) and
did not cause the suspension of anti-TNFa therapy.
Severe SSL was defined in patients with arthritis and/or
mialgia that did not yield with the use of NSAIDs, as well
as in patients that during the course of biological therapy
showed: polyserositis, glomerulonephritis, leukopenia,
thrombocytopenia, thrombotic disease, hypocomplemen-
temia, fever of unknown origin (FUO) neuropsychtatric
SLE.
Measurement of ANA was performed by indirect
immunofluorescence (IFI) using HEp-2 cells, and was
considered positive when titers of ANA exceeded 1:160
(as measured by HEp-2), and for measurement of anti-
dsDNA Crithidia luciliae was used.
Patients with ankylosing spondylitis, psoriatic arthritis,
enteropathic arthropathy, undifferentiated spondyloarthri-
tis and reactive arthritis (excluded patients with uveitis
associated with HLAB27 and juvenile idiopathic arthritis
associated with enthesitis) who had received anti-TNFa
therapy (infliximab, adalimumab or etanercept) for over 1
year were analyzed for the development of LLS, in addi-
tion to measuring the values of ANA ≥ 1:160 (measured
by HEp-2) and anti-dsDNA (measured by IIF).
Statistical analysis
Statistical parameters were described by appropriate
central trend and dispersion measures. Values of ANA ≥
1:160 versus < 1:160 and anti-dsDNA present versus
absent, were dichotomized. A descriptive analysis for
sex, age, and type of disease was made using mean and
range. A multivariate logistic regression analysis was
used to assess binary variables: treatment with inflixi-
mab, another immunosuppressant treatment. The statis-
tical significance of differences in frequency of variable
“signs and symptoms of LLS” was determined by Fish-
er’s exact test and p values were considered significant
when < 0.05 (Svejgaard and Ryder, 1994).
Results
There was not a high prevalence of LLS in patients with
spondyloarthritis treated with anti TNFa therapy. In
total, 7.01% of patients treated anti TNF had titers of
Table 1 Clinical and demographic data of the cohort (n =
57)
Characteristics N = 57 (% or
range)
Male/Female (%) 39/18 (68.4/31.6)
Mean Age (range) 41.2 (23-66)
Type of Spondyloarthritis (%)
Ankylosing Spondylitis 8 (14)
Reactive arthritis 16 (28)
Undiffenciated Spondyloarthritis 22 (38.6)
Psoriatic arthritis 7 (12.3)
Enteropathic artritis 4 (7.1)
Patients treated with IFX (%) 28 (49.1)
Patients treated with ADA (%) 19 (33.3)
Patients treated with ETP (%) 10 (17.6)
Mean duration of therapy with IFX in months
(range)
18 (1-78)
Mean duration of therapy with ADA in months
(range)
13 (1-88)
Mean duration of therapy with ETP in months
(range)
7 (1-38)
ANA positive (%) 4 (7.01)
Anti dsDNA (%) 2 (3.5)
Moderate lupus-like symptoms (%) 0
Severe lupus-like symptoms (%) 1
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of dsDNA. However, only one patient (1.75% n = 1)
experienced clinical symptoms of LLS; this was a female
patient with a history of psoriatic arthritis of 5 years of
evolution, diagnosed with severe psoriasis since the age
of 23 years. Besides that the patient was 50 years old
and had received anti TNF therapy for over 2 years, she
presented annular polycyclic lesions (Figure 1) on the
anterior aspect of the arm (subacute cutaneous lupus)
with polyserositis (Figure 2), which improved with anti
TNF therapy discontinuation and low potency corticos-
teroid. This patient had ANA > 1:320, presence of anti-
dsDNA by IIF and high titers by ELISA (≥ 25 IU/L).
The rest of the patients presenting ANA (+) and anti-
dsDNA (+) did not develop SLL, two of them were diag-
nosed with enteropathic arthritis and one patient with
psoriatic arthritis. There was no positivity for ANA in
patients with ankylosing spondylitis, reactive arthritis or
undifferentiated spondyloarthritis.
Discussion
The presence of LLS secondary to anti-TNFa therapy in
patients with SpA appears to be less frequently observed
compared with patients with RA, probably because in the pathogenesis of SpA large numbers of circulating
autoantibodies have not been found, may be due to the
fact that LLS is an entity associated purely to innate
immunity with little central role of B and T cells. In this
study signs and symptoms associated with LLS were
observed only in one patient with psoriatic arthritis,
with severe and long-standing disease, emphasizing that
according to medical literature in psoriatic arthritis and
psoriasis anti-CCP antibodies have been detected only
in 5-12.5% of the population [25].
As for the production of autoantibodies, a fourth
hypothesis is now considered as the most solid and has
to do with the system of clearance and presentation of
apoptotic material by the adhesion molecule CD44. This
molecule is involved in phagocytosis of apoptotic neu-
trophils; TNFa overregulates the cell expression of
CD44, which, at start of the biologic therapy with anti-
TNFa, a reduction in clearance occurs; [26,27] however,
LLS is still a rare disease and there are reviews where
risk factors for its development such as ANA presence
before treatment, appearance of anti-nucleosome anti-
body, the antibody isotype and, of course, the genetic
polymorphism of anti-TNFa, are considered [28-30].
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Figure 1 Papulosquamous lesions on the arm of a patient
typical of subacute cutaneous lupus.
Figure 2 Pericardial effusion with pleural effusion.
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